No Data
An Intrinsic Calculation For GemPharmatech Co., Ltd. (SHSE:688046) Suggests It's 48% Undervalued
Pharmaron Biotech (688046.SH) will distribute cash dividends for the year 2023 on August 7, with a dividend of 0.16 yuan per share.
Pharmaron Biotech (688046.SH) announced that it will distribute its 2023 annual dividends on August 7, 2024.
Yao Kang Biological (688046.SH): Shareholder Qingdao National Medicine accumulatively reduced its shareholding by 1.0880%.
On July 31st, Gelunhui reported that PharmaKang Biological (688046.SH) received the Notification Letter of Shareholding Reduction from Qingdao National Pharmaceutical, a shareholder who owns more than 5% of the shares, on July 31st, 2024. Between October 31st, 2023 and July 31st, 2024, Qingdao National Pharmaceutical reduced its total shareholding in the company by 4.4608 million shares, or 1.0880% of the total share capital of the company, through block trading and centralized bidding.
Yaokang Biotechnology (688046.SH): Cumulative repurchase of 1.522 million shares of company's stock.
On July 31, Gelun Hui announced that Yakang Biotechnology (688046.SH) had repurchased a total of 1.522 million shares of the company through the Shanghai Stock Exchange trading system using the centralized competitive trading method, as of July 31, 2024, accounting for 0.3712% of the company's total share capital of 410,000,000 shares. The highest price for repurchase transactions was 19.17 yuan/share, and the lowest price was 11.89 yuan/share. The total amount paid for this was RMB 23.8625 million yuan (excluding stamp duty, transaction commission and other transaction costs).
Yaokang Biotechnology (688046.SH): Spent a total of 23.86 million yuan to repurchase 0.3712% of shares.
On July 1st, Gelunhui announced that, by June 30th, 2024, the company had repurchased a total of 1,521,975 shares through the centralized bidding trading method on the Shanghai Stock Exchange, accounting for 0.3712% of the total share capital of 410,000,000 shares. The highest repurchase price was 19.17 yuan/share and the lowest was 11.89 yuan/share, with a total payment of 23,862,462.57 yuan (excluding stamp duty, transaction commission and other transaction fees).
Is GemPharmatech (SHSE:688046) A Risky Investment?
Investor Optimism Abounds GemPharmatech Co., Ltd. (SHSE:688046) But Growth Is LackingNo Data
